ODTX · Odyssey Therapeutics, Inc.
$18.72
+1.05 (+5.94%)
At close · Jul 24
Going-concern doubt
— cleared Jun 17, 2026
The latest filing states the doubt was alleviated.
“Upon closing of the IPO and concurrent private placement, and receipt of the associated cash proceeds, the Company believes the conditions that raised substantial doubt have been resolved. The Company believes that its existing cash, cash equivalents and marketable securities of $175.7 million as of March 31, 2026, together with the additional net proceeds of $288.7 million received from the IPO, concurrent private placement and the underwriters' exercise of the option to purchase additional shares of common stock, will be sufficient to allow the Company to fund operations at least twelve months from the date that the condensed consolidated financial statements are issued.”View the 10-Q filed Jun 17, 2026
Market Cap
$896.26M
Shares
48.03M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-12-04 | New | Biotechnology | $214,025,200 | $214,025,200 | 06b |
| 2024-08-14 | Amendment | Biotechnology | $121,080,000 | $117,210,000 | 06b |
| 2023-12-15 | New | Biotechnology | $106,000,000 | $97,130,000 | 06b |
| 2022-10-27 | New | Biotechnology | $174,909,939 | $168,009,933 | 06b |
| 2021-10-14 | New | Biotechnology | Indefinite | $91,629,837 | 06b |
Showing 1–5 of 5 filings